Compare Marriott International Inc (MAR) vs TG Therapeutics Inc (TGTX) Price & Performance

Marriott International (MAR) trades at $361.08, up 1.28% with bullish technical signals and strong institutional support. The company shows steady revenue growth to $26.19B in 2025 with a 9.62% net margin, though valuation metrics appear elevated with a P/E of 37.38. Recent earnings beat expectations in Q1 and Q2 2026, while analysts maintain a consensus price target of $386.71 with 44% buy ratings.

MAR presents growth potential through travel recovery and strategic partnerships, but faces risks from high debt levels (58.83% debt-to-asset ratio) and economic sensitivity. The stock's technical strength and fundamental growth support a positive outlook, though investors should monitor debt management and macroeconomic impacts on travel demand.

TG Therapeutics (TGTX) trades at $53.34, up 0.74% today, but faces bearish technical signals despite strong profitability metrics like a 55.22% net income margin. Recent earnings misses and a shareholder investigation create headwinds, though revenue growth and a high analyst buy consensus of 84.62% suggest underlying strength. The stock's current price is near key support at $52, with resistance at $54.

The outlook is mixed: robust revenue growth and institutional buying support upside toward the $80.50 consensus target, but earnings misses and legal risks pose challenges. Investors should weigh the company's MS therapy momentum against execution and regulatory uncertainties for balanced risk-reward assessment.